Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

20211,695 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Memorial Sloan Kettering Cancer Center

B. Yа. Alekseev · Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

Sun Young Rha · Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

Camillo Porta · Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

Masatoshi Eto · Kyushu University

Thomas Powles · Royal Free London NHS Foundation Trust

Abstract

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 14, pp. 1289-1300

DOI: 10.1056/nejmoa2035716

Field-Weighted Citation Impact: 197.44